Clinical Trial Update: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the efficacy and safety of RO7790121 in adults with moderate to severe rheumatoid arthritis who have not responded to or cannot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RO7790121

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 2 | Status: RECRUITING